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Abstract
Background: Smear-positive pulmonary TB is the most infectious form of TB. Previous studies on the effect of HIV and
antiretroviral therapy on TB treatment outcomes among these highly infectious patients demonstrated conflicting results,
reducing understanding of important issues.
Methods: All adult smear-positive pulmonary TB patients diagnosed between 2008 and 2010 in Malawi’s largest public,
integrated TB/HIV clinic were included in the study to assess treatment outcomes by HIV and antiretroviral therapy status
using logistic regression.
Results: Of 2,361 new smear-positive pulmonary TB patients, 86% had successful treatment outcome (were cured or
completed treatment), 5% died, 6% were lost to follow-up, 1% failed treatment, and 2% transferred-out. Overall HIV
prevalence was 56%. After adjusting for gender, age and TB registration year, treatment success was higher among HIV-
negative than HIV-positive patients (adjusted odds ratio 1.49; 95% CI: 1.14–1.94). Of 1,275 HIV-infected pulmonary TB
patients, 492 (38%) received antiretroviral therapy during the study. Pulmonary TB patients on antiretroviral therapy were
more likely to have successful treatment outcomes than those not on ART (adjusted odds ratio : 1.83; 95% CI: 1.29–2.60).
Conclusion: HIV co-infection was associated with poor TB treatment outcomes. Despite high HIV prevalence and the
integrated TB/HIV setting, only a minority of patients started antiretroviral therapy. Intensified patient education and
provider training on the benefits of antiretroviral therapy could increase antiretroviral therapy uptake and improve TB
treatment success among these most infectious patients.
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Introduction
Approximately one third of the world’s population is infected
with tuberculosis (TB) bacilli and at risk of developing active TB
[1]. In 2010, there were an estimated 12 million TB cases,
including 8.8 million incident cases [1]. Smear-positive pulmonary
TB (PTB) constitutes 34% of new TB cases [2] and is most likely a
source of TB transmission in the community. In sub-Saharan
Africa, high HIV prevalence increases the risk of developing TB.
An estimated 40% of African TB cases were HIV co-infected in
2010, and 24% of 1.45 million TB deaths globally were among
HIV-infected people [1].
Due to the high HIV prevalence among TB patients, WHO
recommends the Three I’s: intensified TB screening among HIV-
infected individuals, provision of isoniazid preventive therapy
(IPT), and infection control [3]. Adoption of the comprehensive
service package, in particular provision of IPT, by the Malawi
national HIV programme was a challenge due to its implemen-
tation requirements. However, Malawi’s national HIV pro-
gramme started providing IPT among pre-ART patients in 2011
[4].
Treatment success in TB patients is a major challenge in TB
programmes. TB treatment outcomes (cured, treatment complet-
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ed, died, treatment failure, lost to follow-up (LTFU) or transferred-
out) are known to be influenced by a number of factors including
HIV co-infection, but the evidence on what factors are most
influential appears inconclusive. While some studies found lower
TB cure rates among TB/HIV patients [5,6], other studies
reported comparable TB cure rates among those TB/HIV co-
infected to those infected only with TB [7,8]. Most of these studies
were limited by a number of factors. First, they were conducted
largely prior to the widespread use of ART [5–6], which improves
survival [9]. Second, other studies showed reduction in mortality
among HIV-infected TB patients who accessed antiretroviral
therapy (ART) [10–12]; however, these studies focused on ART
and not TB outcomes, reducing their application to strengthen TB
programmes.
Understanding TB treatment outcomes of new smear-positive
PTB cases may provide an indication of the effectiveness of
national TB programmes. We, therefore conducted a study to
explore TB treatment outcomes of new smear-positive adult PTB
cases among those who accessed treatment at Malawi’s largest
public TB registration site, Martin Preuss Centre (MPC), in the
capital, Lilongwe. MPC integrates TB and ART services.
Therefore, we were able to stratify by HIV and ART status to
understand better the role of these critical factors.
Methods
Setting
The study was conducted at the Martin Preuss Centre (MPC),
an integrated TB/HIV clinic run by the Malawi Ministry of
Health’s Lilongwe District Health Office in partnership with the
Lighthouse Trust. MPC, described in detail previously [13], has
three units: HIV testing and counseling, ART, and TB which
includes sputum submission. ‘‘Opt-out’’ HIV testing and counsel-
ing services are also provided within the TB unit; over 95% know
their HIV status before starting TB treatment. MPC registers
approximately 3,200 TB patients annually. Diagnosis of TB is
based on clinical examination, sputum smear microscopy, chest
radiography and other investigations as appropriate for extra-
pulmonary disease. Once diagnosed with TB, patients are
recorded in the national TB register by the district TB officer.
The Malawi National TB control (NTP) program classifies new
smear-positive PTB patients as, ‘‘patients with positive smear
result who have never taken anti-tuberculosis drugs for more than
Table 1. Patient characteristics by TB treatment outcomes for new smear-positive TB patients at Martin Preuss Centre between
January 2008 and December 2010.
Characteristics
Total
(Column: #, %) TB treatment outcome
Success Died LTFU* Transfer out failure P-value
Total 2,361 2,041 86% 110 5% 146 6% 50 2% 14 1%
Sex 0.010
Male 1,460 62% 1,238 85% 73 5% 103 7% 39 3% 7 1%
Female 901 38% 803 89% 37 4% 43 5% 11 1% 7 1%
Age 0.030
15–24 481 20% 415 86% 17 4% 37 8% 8 2% 4 ,1%
25–34 1,023 43% 893 87% 35 3% 61 6% 28 3% 6 1%
35–44 525 22% 458 87% 27 5% 30 6% 8 2% 2 ,1%
45–54 186 8% 155 83% 18 10% 9 5% 3 2% 1 1%
$55 146 6% 120 82% 13 9% 9 6% 3 2% 1 1%
Treatment site$ 0.272
MPC 943 40% 801 85% 22 2% 87 9% 26 3% 7 1%
Other 1,416 60% 1,238 87% 88 6% 59 4% 24 2% 7 ,1%
TB registration year ,0.001
2008 841 36% 753 90% 43 5% 19 2% 16 2% 10 2%
2009 869 37% 729 84% 39 4% 87 10% 12 1% 2 ,1%
2010 651 28% 559 86% 28 4% 40 6% 22 3% 2 ,1%
HIV status£ 0.017
HIV positive 1,275 56% 1,086 85% 72 6% 84 7% 28 2% 5 ,1%
HIV negative 989 44% 875 88% 31 3% 56 6% 18 2% 9 1%
ART status¥ 0.014
On ART 492 39% 437 89% 16 3% 28 6% 8 2% 3 1%
Not on ART 783 61% 649 83% 56 7% 56 7% 20 3% 2 ,1%
success = cured or treatment complete,
¥Included HIV positive only,
£97 TB cases had missing HIV status,
$2 TB cases had missing treatment site.
*LTFU= lost to follow-up.
doi:10.1371/journal.pone.0056248.t001
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one month’’ [14]. All new adult TB cases are treated with the
standard WHO regimen I, consisting of two months of daily
rifampicin (R), Isoniazid (H), pyrazinamide (Z) and ethambutol
(E), followed by four months of RHE.
Approximately 50% of patients initiate and continue TB
treatment at MPC; the rest initiate at MPC but choose to
continue their treatment at one of 18 peripheral health facilities in
accordance with NTP decentralization efforts. Treatment out-
comes of all patients who initiate at MPC regardless of where they
continue treatment are recorded and updated using TB treatment
cards in the MPC central TB register. The Malawi NTP defines
TB treatment outcomes as: 1) cured: a patient who was smear-
positive at diagnosis and has smear-negative results at, or one
month prior to, completion of TB treatment; 2) treatment
completed: a patient who completed treatment (i.e. took a full
course of treatment) but for whom smear results are not available
on, or one month prior, to the completion of TB treatment; 3)
failure: a patient who remains, or returns, smear-positive at five
months or more during TB treatment; 4) death: a patient who died
from any cause during TB treatment; 5) lost to follow-up: a patient
who stopped TB treatment for more than two months; 6)
transferred-out: a patient who (presumably) completed TB
treatment at another TB registration site. Deaths are ascertained
mainly through active follow-up.
MPC also provides ART to HIV-infected individuals. All TB
patients diagnosed with HIV were eligible for ART and expected
to initiate ART within two months of TB registration. ART was
co-administered with TB treatment and available for all patients
regardless of where they chose to continue TB treatment.
Study Design and Population
We included all new smear-positive adult PTB patients ($15
years) who registered and initiated TB treatment at MPC between
January 2008 and December 2010. Patients who completed TB
treatment at MPC or a peripheral site were included.
Data Collection and Data Analysis
Variables for all new smear-positive PTB cases were collected
from routine programme data including TB registers and patient
treatment cards. Variables included TB registration number,
registration date, age, gender, HIV status, ART status and TB
treatment outcome. Data were entered and cleaned in a MS
Access database and analyzed in STATA 10.0. We used chi-
square tests to compare patient characteristics and all TB
treatment outcomes stratified by HIV and ART status. TB cases
with missing treatment outcomes were excluded from further
analysis. The effects of HIV and ART status on TB treatment
outcome were examined using logistic regression models. TB
Table 2. Baseline characteristics and TB treatment outcomes of new smear-positive adult PTB patients by HIV status at Martin
Preuss Centre between January 2008 and December 2010.
Characteristics Total [n (%)] HIV Positive [n (%)] HIV Negative [n (%)] P-value
Overall 2,264 1,275 56% 989 44%
Gender 0.004
Male 1,400 62% 755 59% 645 65%
Female 864 38% 520 41% 344 35%
Age at TB registration ,0.001
15–24 460 20% 169 13% 291 29%
25–34 985 44% 619 49% 366 37%
35–44 505 22% 350 27% 155 16%
45–54 173 8% 100 8% 73 7%
$55 141 6% 37 3% 104 10%
TB Treatment site 0.029
MPC 912 40% 533 42% 379 38%
Other 1,352 60% 742 58% 610 62%
TB registration year 0.070
2008 791 35% 421 33% 370 37%
2009 843 37% 496 39% 347 35%
2010 630 28% 358 28% 272 28%
TB Treatment outcome¥ 0.017
Treatment success 1,960 87% 1085 85% 875 88%
Cured 1,601 82% 869 80% 732 84%
Completed 359 18% 216 20% 143 16%
Lost to follow-up 140 6% 84 7% 56 6%
Treatment failure 14 ,1% 5 ,1% 9 1%
Died 103 5% 72 6% 31 3%
Transfer-out 46 2% 28 2% 18 2%
¥110 TB cases had unknown Tb treatment outcome and treatment success = cured/completed.
chi-square test for difference.
doi:10.1371/journal.pone.0056248.t002
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treatment outcome was categorised as treatment success (‘‘cured’’
or ‘‘treatment completed’’) versus all other treatment outcomes.
The final multivariable model was determined using forward
selection, including explanatory variables with a two-sided p-value
of #0.05. Age group, in 10-year bands, and gender were included
a priori in the final multivariable logistic regression model. Linear
trends for treatment success were explored using chi-square tests.
Statistical significance for all analyses was set at the p#0.05 level
and 95% confidence intervals (CI) were calculated throughout.
Ethical Considerations
The study was approved by the Malawi National Health
Science Research Committee and the Ethics Advisory Group of
the International Union Against Tuberculosis and Lung Disease in
Paris, France. The data for the study did not include any personal
identifiers. The ethics committees waived the need for patient
consent because the study used routine programmatic data that
did not include any personal identifiers.
Results
Study Population
Between January 2008 and December 2010, 2,478 new, smear-
positive, adult PTB cases were registered at MPC. Men comprised
62% (1,530) of all patients. The median age was 31 years
(Interquartile range (IQR) 26–38 years). There were no age
differences across years of TB registration. A total of 117 (5%)
patients had unknown TB treatment outcome and were excluded
in further analyses. Of the remaining 2,361, 86% had treatment
success (1664 were cured and 376 completed treatment), 5% died,
6% were LTFU, 2% transferred-out and 1% had treatment failure
(Table 1). Treatment success decreased from 90% in 2008 to
84% and 86% in 2009 and 2010, respectively (test for trend p
=0.013). The proportions of LTFU were higher in 2009 (10%)
and 2010 (6%) compared to 2008 (2%).
Comparison of Smear-positive PTB Patient Treatment
Outcomes by HIV Status
Most patients (2,264, 96%) knew their HIV status. HIV
prevalence was 56%: 60% in women and 54% in men. HIV-
negative patients had slightly better TB outcomes compared to
HIV-positive patients. Of HIV-negative patients, 88% had
successful treatment outcomes compared to 85% of HIV-positive
patients. More HIV-infected TB patients died (6%) compared to
HIV-negative patients (3%) (p= 0.034) (Table 2). In univariable
logistic regression analyses, being female (OR =1.45, 95% CI
1.12–1.87, p= 0.005) and being HIV-negative (OR 1.34, 95% CI
1.05–1.72, p = 0.019) were both associated with successful TB
treatment outcome while age (p = 0.323) and treatment site
(p = 0.147) were not associated (Table 3). Compared to 2009,
treatment success was higher in 2008 (OR=1.80 95% CI 1.34–
2.43) but similar to 2010 (OR=1.23 95% CI 0.92–1.65). After
adjusting for age, gender and TB registration year, treatment
success among HIV-negative PTB cases increased compared to
HIV-infected peers (adjusted OR=1.49, 95% CI 1.14–1.94).
Table 3. Factors associated with TB treatment success among new smear-positive TB patients at Martin Preuss Centre between







HIV Status 0.019 0.003
HIV positive 1,275 56% 1.00 1.00
HIV negative 989 44% 1.34 (1.05–1.72) 1.49 (1.14–1.94)
Gender 0.005 0.002
Male 1,400 62% 1.00 1.00
Female 864 38% 1.45 (1.12–1.87) 1.52 (1.17–1.99)
Age category 0.323 0.065
15–24 460 20% 0.90 (0.65–1.25) 0.76 (0.54–1.06)
25–34 985 44% 1.00 1.00
35–44 505 22% 0.98 (0.71–1.36) 1.07 (0.77–1.48)
45–54 173 8% 0.71 (0.46–1.10) 0.70 (0.45–1.10)
$55 141 6% 0.66(0.41–1.06) 0.57 (0.35–0.93)
TB Registration year ,0.001 ,0.001
2008 791 35% 1.80 (1.34–2.43) 1.79 (1.33–2.41)
2009 843 37% 1.00 1.00
2010 630 28% 1.23 (0.92–1.65) 1.22 (0.91–1.63)
TB Treatment site 0.147
MPC 912 40% 1.20 (0.94–1.53) -
Other 1,352 60% 1.00
*P-value for likelihood ratio test,
Adjusted for sex, age, HIV status and TB registration year,
¥Treatment success = cured/completed treatment.
doi:10.1371/journal.pone.0056248.t003
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Comparison of Smear-positive PTB Patient Treatment
Outcomes by ART Status
Of the 1,275 HIV-infected new smear-positive PTB cases, 492
(38%) received ART during the study period. There were no
significant differences in terms of gender and age distributions
between those on ART and not. However, the proportion of
patients on ART increased from 17% in 2008 to almost 40% in
2010 (p,0.001). Patients on ART had more successful treatment
outcomes (89%) compared to those not on ART (83%) (p = 0.014).
TB patients who were on ART were less likely to die than those
not on ART (adjusted OR =0.46 95% CI 0.26–0.83). In
multivariable logistic regression, treatment success was higher
among smear-positive PTB patients on ART than among those
not on ART (adjusted OR =1.83, 95% CI: 1.29–2.60) (Table 4).
Discussion
This is one of the largest studies to examine the effects of HIV
and ART status on TB treatment outcomes among new smear-
positive PTB patients in sub-Saharan Africa. In our study, overall
treatment success was 86%, indicating an overall positive
programme outcome. Fifty six percent of smear-positive PTB
patients were HIV co-infected and HIV co-infection was
associated with a slightly poorer TB treatment outcome, even
after adjusting for gender, age and year of TB registration. Only
38% of the TB/HIV new smear-positive co-infected patients were
on ART. Those on ART had successful TB treatment outcomes
compared to those not on ART.
Similar to other studies [15,16], we found a high proportion of
smear-positive PTB among individuals aged 15–44 years; the same
ages are at highest risk of HIV in Malawi [17]. However, HIV
prevalence among our smear-positive PTB patients (56%) was
lower than the national HIV prevalence of 68% among all TB
forms [18]. This finding is likely because the national estimation of
HIV prevalence in TB-infected individuals includes those with
smear-negative PTB, which is quite common among HIV-infected
individuals [19].
As expected, both HIV and ART status influenced TB
treatment outcomes. In general, HIV-infected individuals were
less likely to have successful treatment outcomes and were twice as
likely to die as compared to HIV-negative individuals. Among
HIV-infected smear-positive PTB adults, those on ART had
slightly higher likelihood of successful treatment outcomes
compared to those not on ART. ART enhances the immune
response among HIV-infected TB patients, and this consequently
leads to improved survival [20]. More dramatically, we also found
a 50% reduction in mortality among TB patients on ART
compared to those not on ART, an indication of the positive effect
of TB/ART co-infection treatment, which echoes similar findings
from previous studies [9,21].
Despite the well-known benefit of ART and the integrated TB/
HIV care model at MPC, only 38% of HIV-infected new smear-
positive individuals received ART during TB treatment. The low
ART uptake is likely due to several factors. First, some patients
might be reluctant to take ART and TB drugs simultaneously due
to concerns about pill burden and drug interactions. Second, the
national ART guidelines recommend a guardian before ART
initiation; the absence of a guardian may delay or discourage ART
uptake among TB patients. Lastly, smear-positive PTB patients
are expected to be reviewed by TB clinical officers – a cadre of
mid-level healthcare professionals trained in both TB and ART
management. However, in practice, health surveillance assistants
(the lowest level of healthcare professionals) who are not trained in
ART provision often conduct TB reviews for HIV-infected
Table 4. Factors associated with TB treatment success among new smear-positive TB/HIV co-infected patients at Martin Preuss







ART Status 0.005 0.001
On ART 492 39% 1.61 (1.15–2.25) 1.83 (1.29–2.60)
Not on ART 783 61% 1.00 1.00
Gender 0.031 0.032
Female 520 41% 1.43 (1.03–1.97) 1.44 (1.03–2.01)
Male 755 59% 1.00 1.00
Age at TB registration 0.515 0.373
15–24 169 13% 0.76 (0.48–1.19) 0.70 (0.44–1.12)
25–34 619 49% 1.00 1.00
35–44 350 27% 0.98 (0.67–1.43) 1.06 (0.72–1.55)
45–54 200 8% 0.70 (0.40–1.21) 0.73 (0.42–1.28)
$55 37 3% 1.35 (0.47–3.90) 1.43 (0.49–4.17)
TB Registration year 0.004 ,0.001
2008 421 33% 1.90 (1.30–2.79) 2.17 (1.46–3.22)
2009 496 39% 1.00 1.00
2010 358 28% 1.31 (0.91–1.90) 1.22 (0.84–1.78)
*P-value for likelihood ratio test,
Adjusted for sex, age, ART status and TB registration year,
¥Treatment success = cured/completed treatment.
doi:10.1371/journal.pone.0056248.t004
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individuals, sometimes overlooking the need for ART initiation
[13]. Currently shifting management of smear-positive PTB
patients from health surveillance assistants to TB clinical officers
is under discussion within the Malawi NTP with the aim of
improving routine programme management.
Our results should be viewed in light of the following
limitations. TB treatment outcomes were not available for 5% of
eligible patients and their exclusion might have introduced bias.
However, there were no significant differences in terms of age,
gender and HIV status between patients with and without TB
treatment outcomes. Second, we used only routine programme
data; these do not include information such as viral load and CD4
cell count which may have significant effects on patients’ TB
outcomes. Third, since 165 (34%) of HIV-infected individuals on
ART did not have a recorded ART start date, we could not
explore the effect of duration on ART or timing of ART uptake on
TB outcomes. Previous studies found decreased treatment success
for sequential ART initiation [9]. Despite these limitations, the
study findings are useful to inform policy and programmes that
aim to improve management of new smear-positive TB/HIV
patients in Malawi and other comparable settings.
The results of this study suggest several changes that would
likely improve TB outcomes and reduce the duration of
infectiousness especially among TB/HIV co-infected patients in
an an integrated TB/HIV clinic setting. First, although our study
found satisfactory treatment outcomes for smear-positive PTB
patients, this rate decreased from 90% in 2008 to 84% in 2009 and
to 86% in 2010, possibly due to changing LTFU rates. In an effort
to address LTFU, the Malawi HIV programme recommends
active tracing of TB/HIV patients in facilities providing HIV
services, a step that MPC will consider. Second, appropriate and
intensified sensitization on the benefits of ART for both patients
and care providers might increase ART uptake. Lastly, improved
monitoring and evaluation of TB/HIV co-infected patient care,
especially as provided by health surveillance assistants, would
better identify and address obstacles in ART initiation during
follow-up visits.
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